These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 35322234)

  • 1. Androgen receptor activity in T cells limits checkpoint blockade efficacy.
    Guan X; Polesso F; Wang C; Sehrawat A; Hawkins RM; Murray SE; Thomas GV; Caruso B; Thompson RF; Wood MA; Hipfinger C; Hammond SA; Graff JN; Xia Z; Moran AE
    Nature; 2022 Jun; 606(7915):791-796. PubMed ID: 35322234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequence of androgen receptor-targeted vaccination with androgen deprivation therapy affects anti-prostate tumor efficacy.
    Muralidhar A; Gamat-Huber M; Vakkalanka S; McNeel DG
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38772685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma.
    Jiang G; Shi L; Zheng X; Zhang X; Wu K; Liu B; Yan P; Liang X; Yu T; Wang Y; Cai X
    Aging (Albany NY); 2020 Jun; 12(12):11466-11484. PubMed ID: 32579541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen Receptor Antagonists Suppress Immunotherapy in Prostate Cancer.
    Cancer Discov; 2016 Jun; 6(6):569. PubMed ID: 27102077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin.
    Kwilas AR; Ardiani A; Gameiro SR; Richards J; Hall AB; Hodge JW
    Oncotarget; 2016 Apr; 7(17):23498-511. PubMed ID: 27015557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD8
    Wang W; Green M; Choi JE; Gijón M; Kennedy PD; Johnson JK; Liao P; Lang X; Kryczek I; Sell A; Xia H; Zhou J; Li G; Li J; Li W; Wei S; Vatan L; Zhang H; Szeliga W; Gu W; Liu R; Lawrence TS; Lamb C; Tanno Y; Cieslik M; Stone E; Georgiou G; Chan TA; Chinnaiyan A; Zou W
    Nature; 2019 May; 569(7755):270-274. PubMed ID: 31043744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
    Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
    Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer.
    Kyriakopoulos CE; Eickhoff JC; Ferrari AC; Schweizer MT; Wargowski E; Olson BM; McNeel DG
    Clin Cancer Res; 2020 Oct; 26(19):5162-5171. PubMed ID: 32513836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Combination of Anti-PD-L1 Treatment and Therapeutic Vaccination Facilitates Improved Retroviral Clearance via Reactivation of Highly Exhausted T Cells.
    Knuschke T; Kollenda S; Wenzek C; Zelinskyy G; Steinbach P; Dittmer U; Buer J; Epple M; Westendorf AM
    mBio; 2021 Feb; 12(1):. PubMed ID: 33531395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Escape in Prostate Cancer: Known and Predicted Mechanisms and Targets.
    Reva BA; Omelchenko T; Nair SS; Tewari AK
    Urol Clin North Am; 2020 Nov; 47(4S):e9-e16. PubMed ID: 33446324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
    Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
    Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients.
    Pirozyan MR; McGuire HM; Emran AA; Tseng HY; Tiffen JC; Lee JH; Carlino MS; Menzies AM; Long GV; Scolyer RA; Fazekas de St Groth B; Hersey P
    Front Immunol; 2020; 11():372. PubMed ID: 32210968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
    Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells.
    Olson BM; Gamat M; Seliski J; Sawicki T; Jeffery J; Ellis L; Drake CG; Weichert J; McNeel DG
    Cancer Immunol Res; 2017 Dec; 5(12):1074-1085. PubMed ID: 29051161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Boosting anticancer immunotherapy through androgen receptor blockade.
    Pala L; De Pas T; Conforti F
    Cancer Cell; 2022 May; 40(5):455-457. PubMed ID: 35537411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-1β Is an Androgen-Responsive Target in Macrophages for Immunotherapy of Prostate Cancer.
    Wang D; Cheng C; Chen X; Wang J; Liu K; Jing N; Xu P; Xi X; Sun Y; Ji Z; Zhao H; He Y; Zhang K; Du X; Dong B; Fang Y; Zhang P; Qian X; Xue W; Gao WQ; Zhu HH
    Adv Sci (Weinh); 2023 Jun; 10(17):e2206889. PubMed ID: 37092583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Content Screening Using New U2OS Reporter Cell Models Identifies Harmol Hydrochloride as a Selective and Competitive Antagonist of the Androgen Receptor.
    Dellal H; Boulahtouf A; Alaterre E; Cuenant A; Grimaldi M; Bourguet W; Gongora C; Balaguer P; Pourquier P
    Cells; 2020 Jun; 9(6):. PubMed ID: 32560058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Checkpoint blockade accelerates a novel switch from an NKT-driven TNFα response toward a T cell driven IFN-γ response within the tumor microenvironment.
    Aoyama S; Nakagawa R; Nemoto S; Perez-Villarroel P; Mulé JJ; Mailloux AW
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34135102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.